arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

InMed Pharmaceuticals Inc.

INM
$1.47 ▲ +0.01 (+1.03%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

InMed Pharmaceuticals Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.0M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC None
FCF / Share $-0.42
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$820.19K
↓ -26.2%
Net Income Profit after all expenses
$-1.73M
↓ -2.9%
Operating Margin Operating profit as % of sales
-281.3%
↓ -45.6%
FCF / Share Free cash flow per share
$-0.42
↑ +30.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
14
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 28 quarters